AMRX — Amneal Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapSuper Stock

Annual income statement for Amneal Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,094	2,212	2,394	2,794	3,019
Cost of Revenue
Gross Profit	792	796	857	1,020	1,113
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,941	2,307	2,189	2,545	2,625
Operating Profit	153	-94.9	204	249	394
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	31.4	-248	-40.3	-55	139
Provision for Income Taxes
Net Income After Taxes	20.2	-255	-48.7	-73.9	128
Minority Interest
Net Income Before Extraordinary Items
Net Income	10.6	-130	-84	-117	72.1
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	10.6	-130	-84	-117	72.1
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.339	0.406	-0.217	-0.17	0.233